You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNepafenac
Accession NumberDB06802
TypeSmall Molecule
GroupsApproved
DescriptionNepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.
Structure
Thumb
Synonyms
2-amino-3-Benzoylbenzeneacetamide
AHR 9434
AHR-9434
AL 6515
AL-6515
Amfenac amide
Nepafenaco
Nepafenacum
Nevanac
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ilevrosuspension0.3 %ophthalmicAlcon Canada Inc2014-06-01Not applicableCanada
Ilevrosuspension3 mg/mLophthalmicAlcon Laboratories, Inc.2012-12-20Not applicableUs
Nevanacsuspension/ drops1 mg/mLophthalmicAlcon Laboratories, Inc.2005-09-06Not applicableUs
Nevanacsuspension1 mg/mLophthalmicPhysicians Total Care, Inc.2011-08-31Not applicableUs
Nevanacsuspension0.1 %ophthalmicAlcon Canada Inc2008-08-21Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0J9L7J6V8C
CAS number78281-72-8
WeightAverage: 254.2839
Monoisotopic: 254.105527702
Chemical FormulaC15H14N2O2
InChI KeyInChIKey=QEFAQIPZVLVERP-UHFFFAOYSA-N
InChI
InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
IUPAC Name
2-(2-amino-3-benzoylphenyl)acetamide
SMILES
NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Diphenylmethane
  • Phenylacetamide
  • Acetophenone
  • Substituted aniline
  • Aryl ketone
  • Benzoyl
  • Aniline
  • Primary aromatic amine
  • Vinylogous amide
  • Primary carboxylic acid amide
  • Ketone
  • Carboxamide group
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of pain and inflammation associated with cataract surgery.
PharmacodynamicsLow but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours postdose, respectively, following bilateral topical ocular TID dosing of nepafenac ophthalmic suspension, 0.1%. The mean steady-state Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng/ml and 0.422 ± 0.121 ng/ml, respectively, following ocular administration.
Mechanism of actionNepafenac is a prodrug. After penetrating the cornea, nepafenac undergoes rapid bioactivation to amfenac, which is a potent NSAID that uniformly inhibits the COX1 and COX2 activity.
Related Articles
AbsorptionNepafenac rapidly cross the cornea (6 times faster than diclofenac in vitro).
Volume of distributionNot Available
Protein bindingAmfenac has high affinity toward serum albumin proteins. In vitro, the percent bound to human albumin and human serum was 95.4% and 99.1% respectively.
Metabolism

Nepafenac (prodrug) is deaminated to amfenac (active compound) in the ciliary body epithelium, retina, and choroid by intraocular hydrolases. Subsequently, amfenac undergoes extensive metabolism to more polar metabolites involving hydroxylation of the aromatic ring leading to glucuronide conjugate formation.

Route of eliminationAfter oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactivity elimination, accounting for approximately 85% of the dose, while fecal excretion represented approximately 6% of the dose. Nepafenac (prodrug) and amfenac (active compound) were not quantifiable in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicityOcularly applied non-steroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Nepafenac Action PathwayDrug actionSMP00702
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9624
Blood Brain Barrier+0.9918
Caco-2 permeable+0.5581
P-glycoprotein substrateNon-substrate0.7608
P-glycoprotein inhibitor INon-inhibitor0.5471
P-glycoprotein inhibitor IINon-inhibitor0.9209
Renal organic cation transporterNon-inhibitor0.8641
CYP450 2C9 substrateNon-substrate0.8471
CYP450 2D6 substrateNon-substrate0.827
CYP450 3A4 substrateNon-substrate0.6542
CYP450 1A2 substrateInhibitor0.6993
CYP450 2C9 inhibitorInhibitor0.547
CYP450 2D6 inhibitorNon-inhibitor0.882
CYP450 2C19 inhibitorInhibitor0.5714
CYP450 3A4 inhibitorNon-inhibitor0.7118
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7441
Ames testNon AMES toxic0.6193
CarcinogenicityNon-carcinogens0.6932
BiodegradationNot ready biodegradable0.719
Rat acute toxicity2.0064 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9797
hERG inhibition (predictor II)Non-inhibitor0.7681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Suspensionophthalmic0.3 %
Suspensionophthalmic3 mg/mL
Suspensionophthalmic0.1 %
Suspensionophthalmic1 mg/mL
Suspension/ dropsophthalmic1 mg/mL
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6403609 No1998-07-172018-07-17Us
US7834059 No2007-01-312027-01-31Us
US7947295 No2004-06-082024-06-08Us
US8071648 No2005-12-022025-12-02Us
US8324281 No2005-12-022025-12-02Us
US8921337 No2012-03-312032-03-31Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0197 mg/mLALOGPS
logP1.53ALOGPS
logP2.08ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)15.82ChemAxon
pKa (Strongest Basic)1.83ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.18 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity74.46 m3·mol-1ChemAxon
Polarizability26.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857 ]
  2. Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. [PubMed:10850858 ]
  3. Lane SS, Modi SS, Lehmann RP, Holland EJ: Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007 Jan;33(1):53-8. [PubMed:17189793 ]
  4. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R: In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-45. [PubMed:17720067 ]
  5. Bucci FA Jr, Waterbury LD: Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2008 Aug;34(8):1226; author reply 1226-7. doi: 10.1016/j.jcrs.2008.05.019. [PubMed:18655957 ]
External Links
ATC CodesS01BC10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (119 KB)
MSDSDownload (58.1 KB)
Interactions
Drug Interactions
Drug
AbciximabNepafenac may increase the anticoagulant activities of Abciximab.
AcebutololNepafenac may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Nepafenac.
AcenocoumarolNepafenac may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nepafenac.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Nepafenac.
Alendronic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alendronic acid.
AliskirenNepafenac may decrease the antihypertensive activities of Aliskiren.
AlprenololNepafenac may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nepafenac.
AmikacinNepafenac may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideNepafenac may decrease the antihypertensive activities of Amiloride.
AncrodNepafenac may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nepafenac.
Antithrombin III humanNepafenac may increase the anticoagulant activities of Antithrombin III human.
ApixabanNepafenac may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Nepafenac.
ArdeparinNepafenac may increase the anticoagulant activities of Ardeparin.
ArgatrobanNepafenac may increase the anticoagulant activities of Argatroban.
ArotinololNepafenac may decrease the antihypertensive activities of Arotinolol.
AtenololNepafenac may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nepafenac.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nepafenac.
BalsalazideNepafenac may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nepafenac.
BecaplerminNepafenac may increase the anticoagulant activities of Becaplermin.
BefunololNepafenac may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nepafenac.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nepafenac.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nepafenac.
BetaxololNepafenac may decrease the antihypertensive activities of Betaxolol.
BevantololNepafenac may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nepafenac.
BisoprololNepafenac may decrease the antihypertensive activities of Bisoprolol.
BivalirudinNepafenac may increase the anticoagulant activities of Bivalirudin.
BopindololNepafenac may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nepafenac.
BufuralolNepafenac may decrease the antihypertensive activities of Bufuralol.
BumetanideNepafenac may decrease the diuretic activities of Bumetanide.
BupranololNepafenac may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nepafenac.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nepafenac.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nepafenac.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nepafenac.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Nepafenac.
CarteololNepafenac may decrease the antihypertensive activities of Carteolol.
CarvedilolNepafenac may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nepafenac.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nepafenac.
CeliprololNepafenac may decrease the antihypertensive activities of Celiprolol.
CertoparinNepafenac may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nepafenac.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nepafenac.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nepafenac.
CholestyramineCholestyramine can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nepafenac.
Citric AcidNepafenac may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nepafenac.
ColesevelamColesevelam can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineNepafenac may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Nepafenac is combined with D-Limonene.
Dabigatran etexilateNepafenac may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinNepafenac may increase the anticoagulant activities of Dalteparin.
DanaparoidNepafenac may increase the anticoagulant activities of Danaparoid.
DaunorubicinNepafenac may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Nepafenac is combined with Deferasirox.
DesirudinNepafenac may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nepafenac.
DextranNepafenac may increase the anticoagulant activities of Dextran.
Dextran 40Nepafenac may increase the anticoagulant activities of Dextran 40.
Dextran 70Nepafenac may increase the anticoagulant activities of Dextran 70.
Dextran 75Nepafenac may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nepafenac.
DicoumarolNepafenac may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nepafenac.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nepafenac.
DihydrostreptomycinNepafenac may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nepafenac.
DoxorubicinNepafenac may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneNepafenac may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Droxicam.
Edetic AcidNepafenac may increase the anticoagulant activities of Edetic Acid.
EdoxabanNepafenac may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nepafenac.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nepafenac.
EnoxaparinNepafenac may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Nepafenac is combined with Epirizole.
EpirubicinNepafenac may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneNepafenac may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nepafenac.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nepafenac.
EsmololNepafenac may decrease the antihypertensive activities of Esmolol.
Etacrynic acidNepafenac may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Nepafenac.
Ethyl biscoumacetateNepafenac may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Nepafenac.
EtofenamateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Nepafenac.
Evening primrose oilThe risk or severity of adverse effects can be increased when Nepafenac is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Nepafenac.
FenbufenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nepafenac.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nepafenac.
FlunixinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nepafenac.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nepafenac.
Fondaparinux sodiumNepafenac may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nepafenac.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nepafenac.
FramycetinNepafenac may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideNepafenac may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nepafenac.
GentamicinNepafenac may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Haloperidol.
HeparinNepafenac may increase the anticoagulant activities of Heparin.
HirulogNepafenac may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Nepafenac.
HydralazineNepafenac may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nepafenac.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nepafenac.
Hygromycin BNepafenac may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nepafenac.
IbuproxamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Nepafenac.
IdarubicinNepafenac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nepafenac.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nepafenac.
IndenololNepafenac may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nepafenac.
IndoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nepafenac.
IsoxicamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Isoxicam.
KanamycinNepafenac may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nepafenac.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nepafenac.
LabetalolNepafenac may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Nepafenac.
LepirudinNepafenac may increase the anticoagulant activities of Lepirudin.
LevobunololNepafenac may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nepafenac.
LithiumThe serum concentration of Lithium can be increased when it is combined with Nepafenac.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Nepafenac.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nepafenac.
LoxoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nepafenac.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Nepafenac.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nepafenac.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nepafenac.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nepafenac.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nepafenac.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nepafenac.
MesalazineNepafenac may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nepafenac.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Nepafenac.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nepafenac.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nepafenac.
MetipranololNepafenac may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nepafenac.
MetoprololNepafenac may decrease the antihypertensive activities of Metoprolol.
MetrizamideNepafenac may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nepafenac.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nepafenac.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nepafenac.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nepafenac.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nepafenac.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Nepafenac.
NadololNepafenac may decrease the antihypertensive activities of Nadolol.
NadroparinNepafenac may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nepafenac.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Nepafenac.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Nepafenac.
NeomycinNepafenac may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NetilmicinNepafenac may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nepafenac.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nepafenac.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nepafenac.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nepafenac.
OlsalazineNepafenac may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nepafenac.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Nepafenac.
OrgoteinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Orgotein.
OtamixabanNepafenac may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nepafenac.
OxprenololNepafenac may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nepafenac.
PamidronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Nepafenac is combined with Parecoxib.
ParomomycinNepafenac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololNepafenac may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateNepafenac may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nepafenac.
PhenindioneNepafenac may increase the anticoagulant activities of Phenindione.
PhenprocoumonNepafenac may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nepafenac.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nepafenac.
PindololNepafenac may decrease the antihypertensive activities of Pindolol.
PiretanideNepafenac may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nepafenac.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nepafenac.
PlicamycinNepafenac may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nepafenac.
PractololNepafenac may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nepafenac.
ProbenecidThe serum concentration of Nepafenac can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Propacetamol.
PropranololNepafenac may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Nepafenac.
Protein CNepafenac may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeNepafenac may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Nepafenac.
PuromycinNepafenac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nepafenac.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nepafenac.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nepafenac.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nepafenac.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nepafenac.
ReviparinNepafenac may increase the anticoagulant activities of Reviparin.
RibostamycinNepafenac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Risedronate.
RivaroxabanNepafenac may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Nepafenac.
SalicylamideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nepafenac.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Nepafenac.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nepafenac.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nepafenac.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nepafenac.
SotalolNepafenac may decrease the antihypertensive activities of Sotalol.
SpectinomycinNepafenac may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Nepafenac.
SpironolactoneNepafenac may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Nepafenac.
StreptomycinNepafenac may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinNepafenac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineNepafenac may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nepafenac.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nepafenac.
SulodexideNepafenac may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Nepafenac.
TacrolimusNepafenac may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nepafenac.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nepafenac.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nepafenac.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Nepafenac.
TenofovirThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nepafenac.
TepoxalinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nepafenac.
TiludronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tiludronate.
TimololNepafenac may decrease the antihypertensive activities of Timolol.
TobramycinNepafenac may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nepafenac.
TorasemideNepafenac may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nepafenac.
TranilastThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nepafenac.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nepafenac.
TriamtereneNepafenac may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nepafenac.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nepafenac.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Nepafenac.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nepafenac.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nepafenac.
WarfarinNepafenac may increase the anticoagulant activities of Warfarin.
XimelagatranNepafenac may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nepafenac.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Nepafenac.
Zoledronic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nepafenac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857 ]
Comments
comments powered by Disqus
Drug created on September 14, 2010 10:21 / Updated on October 01, 2016 02:24